These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12707577)

  • 1. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets.
    Dörner T; Burmester GR
    Curr Opin Rheumatol; 2003 May; 15(3):246-52. PubMed ID: 12707577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do self-perpetuating B lymphocytes drive human autoimmune disease?
    Edwards JC; Cambridge G; Abrahams VM
    Immunology; 1999 Jun; 97(2):188-96. PubMed ID: 10447731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity.
    Pongratz G; Fleck M
    Curr Pharm Des; 2012; 18(29):4526-36. PubMed ID: 22612739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction.
    Boissier MC; Semerano L; Challal S; Saidenberg-Kermanac'h N; Falgarone G
    J Autoimmun; 2012 Sep; 39(3):222-8. PubMed ID: 22704962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P; Jamin C; Saraux A
    Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases.
    Mariette X
    Joint Bone Spine; 2004 Sep; 71(5):357-60. PubMed ID: 15474382
    [No Abstract]   [Full Text] [Related]  

  • 7. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC; St Clair EW
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.
    Scarsi M; Paolini L; Ricotta D; Pedrini A; Piantoni S; Caimi L; Tincani A; Airò P
    J Rheumatol; 2014 Apr; 41(4):666-72. PubMed ID: 24584924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune diseases. The B cell slayer.
    Matthews R
    Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy.
    Alam J; Jantan I; Bukhari SNA
    Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
    Thurlings RM; Vos K; Gerlag DM; Tak PP
    Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.
    Nakken B; Munthe LA; Konttinen YT; Sandberg AK; Szekanecz Z; Alex P; Szodoray P
    Autoimmun Rev; 2011 Nov; 11(1):28-34. PubMed ID: 21777703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases.
    Lee S; Ballow M
    J Allergy Clin Immunol; 2010 Apr; 125(4):814-20. PubMed ID: 20371395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
    Edwards JC; Cambridge G
    Nat Rev Immunol; 2006 May; 6(5):394-403. PubMed ID: 16622478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
    Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy.
    Bankó Z; Pozsgay J; Gáti T; Rojkovich B; Ujfalussy I; Sármay G
    Clin Immunol; 2017 Nov; 184():63-69. PubMed ID: 28506920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain.
    Hadley I; Jain R; Sreih A
    J Clin Rheumatol; 2014 Apr; 20(3):163-6. PubMed ID: 24662560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.